JP2015508762A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508762A5
JP2015508762A5 JP2014556934A JP2014556934A JP2015508762A5 JP 2015508762 A5 JP2015508762 A5 JP 2015508762A5 JP 2014556934 A JP2014556934 A JP 2014556934A JP 2014556934 A JP2014556934 A JP 2014556934A JP 2015508762 A5 JP2015508762 A5 JP 2015508762A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid residues
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014556934A
Other languages
English (en)
Other versions
JP6411218B2 (ja
JP2015508762A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/074092 external-priority patent/WO2013120553A1/en
Publication of JP2015508762A publication Critical patent/JP2015508762A/ja
Publication of JP2015508762A5 publication Critical patent/JP2015508762A5/ja
Application granted granted Critical
Publication of JP6411218B2 publication Critical patent/JP6411218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. TREM-1に特異的に結合し、それを遮断することができる抗体またはその断片。
  2. PGLYRP1に誘導されるTREM-1の活性化を遮断することができる、請求項1に記載の抗体またはその断片。
  3. 配列番号1(ヒトTREM-1)との結合についてmAb 0170と競合する、請求項1または2に記載の抗体またはその断片。
  4. 配列番号12または配列番号21(カニクイザルTREM-1)との結合についてmAb 0170と競合する、請求項1から3のいずれか一項に記載の抗体またはその断片。
  5. 配列番号1(ヒトTREM-1)のアミノ酸D38〜F48を含むポリペプチドに特異的に結合することができる、請求項1から4のいずれか一項に記載の抗体またはその断片。
  6. 配列番号12(カニクイザルTREM-1)のアミノ酸残基E19〜L26を含むポリペプチドに特異的に結合することができる、請求項1から5のいずれか一項に記載の抗体またはその断片。
  7. 配列番号1(ヒトTREM-1)のアミノ酸残基D38、V39、K40、C41、D42、Y43、T44およびL45のうちの1つ、2つ、3つ、4つ、5つ、6つ、7つまたは全部、ならびにアミノ酸残基E46、K47、F48のうちの1つ、2つ、または全部を含むエピトープを有する、請求項1から6のいずれか一項に記載の抗体またはその断片。
  8. 配列番号1(ヒトTREM-1)のアミノ酸残基D42、E46、D92およびH93のうちの1つ、2つ、3つまたは全部を含むエピトープを有する、請求項1から7のいずれか一項に記載の抗体またはその断片。
  9. 配列番号1(ヒトTREM-1)のアミノ酸残基L31、I86およびV101のうちの1つ、2つ、または全部をさらに含むエピトープを有する、請求項7または8に記載の抗体またはその断片。
  10. 配列番号13(K20A-hTREM-1-Cmyc2-His6)に特異的に結合することができる、請求項1から9のいずれか一項に記載の抗体。
  11. 配列番号14(A24T/Y28F/N30S/R32Q/P70H-cTREM-1-Cmyc2-His6)に特異的に結合することができる、請求項1から10のいずれか一項に記載の抗体。
  12. 配列番号15(A24T/Y28F/N30S/R32Q/E54K-cTREM-1-Cmyc2-His6)に特異的に結合することができる、請求項1から11のいずれか一項に記載の抗体。
  13. 重鎖が、配列番号4もしくは配列番号6のアミノ酸残基31〜35(TYAMH)に対応するCDRH1配列であって、これらのアミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号4もしくは配列番号6のアミノ酸50〜68(RIRTKSSNYATYYAASVKG)に対応するCDRH2配列であって、前記アミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号4のアミノ酸残基101〜110(DMGIRRQFAY)もしくは配列番号6のアミノ酸残基101〜110(DMGQRRQFAY)に対応するCDRH3配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含み;ならびに、軽鎖が、配列番号5もしくは配列番号7のアミノ酸残基24〜38(RASESVDTFDYSFLH)に対応するCDRL1配列であって、これらのアミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号5もしくは配列番号7のアミノ酸残基54〜60(RASNLES)に対応するCDRL2配列であって、これらのアミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号5もしくは配列番号7のアミノ酸残基93〜101(QQSNEDPYT)に対応するCDRL3配列であって、これらのアミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列を含む、請求項1から12のいずれか一項に記載の抗体。
  14. 重鎖が、配列番号4もしくは配列番号6のアミノ酸残基31〜35(TYAMH)に対応するCDRH1配列;および/または配列番号4もしくは配列番号6のアミノ酸50〜68(RIRTKSSNYATYYAASVKG)に対応するCDRH2配列;および/または配列番号4のアミノ酸残基101〜110(DMGIRRQFAY)もしくは配列番号6のアミノ酸残基101〜110(DMGQRRQFAY)に対応するCDRH3配列を含み:ならびに、軽鎖が、配列番号5もしくは配列番号7のアミノ酸残基24〜38(RASESVDTFDYSFLH)に対応するCDRL1配列;および/または配列番号5もしくは配列番号7のアミノ酸残基54〜60(RASNLES)に対応するCDRL2配列;および/または配列番号5もしくは配列番号7のアミノ酸残基93〜101(QQSNEDPYT)に対応するCDRL3配列を含む、請求項13に記載の抗体。
  15. 敗血症または炎症性疾患の治療または予防のための、請求項1から14のいずれか一項に記載の抗体またはその断片を含む医薬。
JP2014556934A 2012-02-15 2012-11-30 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体 Active JP6411218B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201261598968P 2012-02-15 2012-02-15
US61/598,968 2012-02-15
EP12155641 2012-02-15
EP12155641.9 2012-02-15
US201261599447P 2012-02-16 2012-02-16
US61/599,447 2012-02-16
EP12158974.1 2012-03-12
EP12158974 2012-03-12
US201261672799P 2012-07-18 2012-07-18
EP12176892.3 2012-07-18
US61/672,799 2012-07-18
EP12176892 2012-07-18
US201261674434P 2012-07-23 2012-07-23
US61/674,434 2012-07-23
PCT/EP2012/074092 WO2013120553A1 (en) 2012-02-15 2012-11-30 Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018180187A Division JP6740308B2 (ja) 2012-02-15 2018-09-26 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体

Publications (3)

Publication Number Publication Date
JP2015508762A JP2015508762A (ja) 2015-03-23
JP2015508762A5 true JP2015508762A5 (ja) 2016-01-21
JP6411218B2 JP6411218B2 (ja) 2018-10-24

Family

ID=48946140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014556934A Active JP6411218B2 (ja) 2012-02-15 2012-11-30 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
JP2018180187A Active JP6740308B2 (ja) 2012-02-15 2018-09-26 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018180187A Active JP6740308B2 (ja) 2012-02-15 2018-09-26 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体

Country Status (17)

Country Link
US (2) US9000127B2 (ja)
EP (3) EP3196214B1 (ja)
JP (2) JP6411218B2 (ja)
CN (2) CN108103069B (ja)
CY (1) CY1120068T1 (ja)
DK (1) DK2814844T3 (ja)
ES (1) ES2640268T3 (ja)
HR (1) HRP20171585T1 (ja)
HU (1) HUE036955T2 (ja)
LT (1) LT2814844T (ja)
NO (1) NO2814844T3 (ja)
PL (1) PL2814844T3 (ja)
PT (1) PT2814844T (ja)
RS (1) RS56593B1 (ja)
SI (1) SI2814844T1 (ja)
TW (1) TWI605061B (ja)
WO (1) WO2013120553A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3196214B1 (en) * 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
ES2750209T3 (es) * 2012-02-15 2020-03-25 Novo Nordisk As Anticuerpos que se unen a y bloquean al receptor desencadenante expresado en células mieloides-1 (TREM-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP2835641A1 (en) 2013-08-09 2015-02-11 Inotrem Methods and kits for predicting the risk of having a cardiovascular disease or event
EP3026061A1 (en) 2014-11-26 2016-06-01 Novo Nordisk A/S Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
EP2975056A1 (en) 2014-07-17 2016-01-20 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
KR102465120B1 (ko) 2014-07-17 2022-11-10 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2017083682A1 (en) * 2015-11-12 2017-05-18 The Board Of Trustees Of Leland Stanford Junior University Labeled probe and methods of use
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
EP3423493A2 (en) * 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
CN106053831A (zh) * 2016-06-05 2016-10-26 潘时辉 一种用于自身免疫病检测的试剂盒
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
CN108276488B (zh) * 2018-01-26 2020-06-19 四川农业大学 一种鸡髓样细胞触发受体b2多克隆抗体及其制备方法和应用
KR20200139219A (ko) 2018-04-02 2020-12-11 브리스톨-마이어스 스큅 컴퍼니 항-trem-1 항체 및 이의 용도
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
AU2019348534A1 (en) 2018-09-28 2021-05-06 Inotrem Use of soluble TREM-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
EP3999543A1 (en) * 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
CN118546253A (zh) 2019-07-15 2024-08-27 百时美施贵宝公司 针对人trem-1的抗体及其用途
EP4065152A1 (en) 2019-11-25 2022-10-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
CN111157741B (zh) * 2019-12-30 2022-08-16 广州市妇女儿童医疗中心 髓系细胞触发受体1在制备胃炎诊断或治疗试剂中的应用及试剂盒
JP2023529089A (ja) 2020-06-05 2023-07-07 イノトレム コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤
US20230273208A1 (en) 2020-06-05 2023-08-31 Inotrem Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronavirus infection
CA3197465A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
US20240173376A1 (en) 2021-03-12 2024-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of marfan syndrome
BR112023022844A2 (pt) 2021-05-03 2024-01-23 UCB Biopharma SRL Anticorpos
AU2022287235A1 (en) * 2021-06-02 2023-12-14 Inotrem Anti-trem-1 antibodies
WO2023061946A1 (en) 2021-10-11 2023-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass
CN114948849A (zh) * 2022-05-13 2022-08-30 苏州大学附属第一医院 一种含trem1抑制剂的微针、微针系统及其制备方法
CN115586338A (zh) * 2022-09-20 2023-01-10 杭州赛基生物科技有限公司 用于检测可溶性细胞因子受体的试剂盒及其制备方法

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2972257B2 (ja) 1990-01-24 1999-11-08 株式会社日立製作所 パケット交換機
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
ES2154637T3 (es) 1991-05-14 2001-04-16 Univ Connecticut Aportacion de genes dirigidos que codifican proteinas inmunogenicas.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE195656T1 (de) 1991-06-05 2000-09-15 Univ Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
FR2694851B1 (fr) 1992-08-12 1994-12-23 Sgs Thomson Microelectronics Circuit de tirage vers un état déterminé d'une entrée de circuit intégré.
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF THE CYTOKIN IP-10 AS AN ANTI-TUMOR AGENCY
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
JPH08509857A (ja) 1993-01-07 1996-10-22 シーケノム・インコーポレーテッド マススペクトロメトリーによるｄｎａ配列決定法
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US6034217A (en) 1996-09-17 2000-03-07 Wako Pure Chemical Industries, Ltd. Peptidoglycan recognition proteins and their production
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US20030049618A1 (en) 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US20030175858A1 (en) 1997-03-07 2003-09-18 Ruben Steven M. 186 human secreted proteins
WO1998039446A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
US6420526B1 (en) 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6172211B1 (en) 1997-07-11 2001-01-09 Boehringer Ingelheim International Gmbh Nucleic acid encoding tag7 polypeptide
WO1999018126A1 (fr) 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
AU4834999A (en) 1998-06-26 2000-01-17 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US20020197669A1 (en) 2000-12-13 2002-12-26 Bangur Chaitanya S. Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
CA2431177C (en) 2000-12-08 2015-04-14 Baylor College Of Medicine Trem-1 splice variant for use in modifying immune responses
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2003029401A2 (en) 2001-07-13 2003-04-10 Advanced Research And Technology Institute Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
AU2002322394A1 (en) 2001-07-30 2003-02-17 Eli Lilly And Company Method for treating diabetes and obesity
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
EP1439857B1 (en) 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
AU2003215761A1 (en) 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2003265787A1 (en) 2002-08-29 2004-03-19 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
GB0305478D0 (en) 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP1692506A4 (en) 2003-11-17 2008-01-09 Janssen Pharmaceutica Nv MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2005113606A2 (en) 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
CA3058450A1 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
AU2008205538A1 (en) * 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via TREM-1
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー／エス Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
EP2232271B1 (en) 2007-12-19 2019-09-11 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
US20090234202A1 (en) 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
ES2506116T3 (es) 2008-05-23 2014-10-13 Biocartis Nv Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
BRPI0917130A2 (pt) 2008-08-25 2015-12-01 Centocor Ortho Biotech Inc biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
AU2010207721B2 (en) 2009-01-23 2015-03-26 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2010141469A2 (en) 2009-06-01 2010-12-09 Case Western Reserve University Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases
JP2012529463A (ja) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
KR101251023B1 (ko) 2009-11-05 2013-04-03 주식회사유한양행 신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
KR20130098161A (ko) 2010-04-30 2013-09-04 알렉시온 파마슈티칼스, 인코포레이티드 인간에서 감소된 면역원성을 갖는 항체
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
US9856365B2 (en) * 2011-08-31 2018-01-02 Radici Plastics Usa, Inc. Compositions of polyhydric alcohols and polyamides
EP3196214B1 (en) * 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)

Similar Documents

Publication Publication Date Title
JP2015508762A5 (ja)
HRP20171585T1 (hr) Antitijela koja vezuju i blokiraju aktivirajući receptor eksprimiran na mijeloičnim stanicama 1 (trem-1)
AR081556A1 (es) Proteinas de union al antigeno humanizadas
JP2020500538A5 (ja)
JP2017528476A5 (ja)
HRP20192233T1 (hr) Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
AR123305A2 (es) Proteínas de unión a antígeno
HRP20170882T1 (hr) Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse
JP2012504955A5 (ja)
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2012505912A5 (ja)
JP2018521638A5 (ja)
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
JP2015508763A5 (ja)
NZ623347A (en) Novel anti-dr5 antibody
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
AR086579A1 (es) Proteinas de union a antigeno
JP2011528902A5 (ja)
JP2014511179A5 (ja)
JP2016507470A5 (ja)
JP2017532313A5 (ja)
JP2014205674A5 (ja)
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
JP2009511480A5 (ja)